-
2024-513371-41-00
4
2024-04-25
Severe uveitis of Behçet’s disease
-
2022-501119-14-01
4
2024-04-16
Ulcerative Colitis
-
2023-506753-38-00
4
2024-04-16
metastatic gastric adenocarcinoma
-
2023-504865-21-00
5
2024-04-15
Essential Thrombocythemia patients who have an inadequate response to
-
2023-508531-30-00
4
2024-03-25
grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
-
2022-501554-11-00
4
2024-03-21
Patients with previously untreated Richter’s syndrome (RS), defined as
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2024-514101-65-00
4
2023-12-21
Multiple Myeloma
-
2023-504555-27-00
5
2023-11-28
Myelodysplastic syndrome (MDS)
-
2022-501057-36-00
5
2023-10-24
ANCA-associated vasculitis
-
2022-502019-12-00
5
2023-09-14
acute myeloid leukemia
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2024-513811-29-00
5
2023-07-03
Cardiogenic Shock
-
2024-512999-35-00
4
2023-06-23
Patients with HER 2 negative locally advanced, recurrent or metastatic
-
2024-517953-28-00
7
2023-06-07
Treatment in haematopoietic stem cell transplantation
-
2024-511936-28-00
1
2023-05-12
Relapsed/refractory hematological malignancies
or advanced/metastatic
-
2022-501494-39-00
5
2023-03-28
Uncontrolled Hypertension IN patients with moderate to severe chronic
-
2024-514929-33-00
5
2023-03-27
PANCREATIC FISTULA
-
2022-501335-16-00
10
2023-01-16
Interstitial lung disease
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-513191-17-00
4
2022-02-03
autoimmune hemolytic anemia
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)